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Natural products with therapeutic potential in 
melanoma metastasis 
A. AlQathamaa,b, J.M. Prieto, a* 
Malignant melanoma is the most aggressive form of skin cancer and accounts for about 3% of all 
cases of malignant tumour. Its incidence is increasing worldwide and it is becoming resistant to 
current therapeutic agents. Natural products continue to provide lead cytotoxic compounds for 
cancer treatment but less attention has been given to antimigratory compounds. This paper 
systematically and critically surveys all natural products with direct in vitro and in vivo 
pharmacological effects on migration and/or metastasis of melanoma cells and maps the 
mechanisms of action for these underexploited properties. As a result, over 30 natural active 
principles are described acting mainly through their antagonistic effects upon the TNF-α and EP2 
receptors or the suppression of several protein kinases involved in metastatic pathways such as 
RAS, PI3K, ERK and FAK. Also, some were able to reduce the level of mesenchymal biomarkers 
such as N-cadherin and/or elevate the expression of other molecules such as E-cadherin. 
Consequently, downstream transcription factors namely NF-kB, AP-1, ATF-2, CREB, and HIF 
were inactivated leading to diminished production of MMPs, IL-1, IL-6, COX-2, VEGF and GM-
CSF. This review also discusses the opportunity of combination therapies based on natural 
products and approved drugs, such as the combination of EGCG and dacarbazine, or the 
combination of  two natural compounds such as quercetin and sulforaphane.   
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1 Introduction 
Melanoma is a highly resistant and malignant cancer 
accounting for about 3% of all cases of malignant 
tumours. 1 Its incidence has increased faster than that 
of any other cancer type during recent decades. 
Although melanoma accounts for only 4% of all skin 
cancer cases, it is the most aggressive and causes 
approximately 80% of all deaths from skin cancer. 2 
Malignant melanoma has been described as a 
sequential process that originates from an atypical 
benign nevus followed by anomalous growth and 
dysplasia, resulting in a pre-malignant lesion. 
Malignant melanocytes will then enter into radial 
growth phase by proliferating horizontally within the 
epidermis. This is followed by a vertical growth 
phase, where malignant cells acquire the ability to 
invade the basement membrane thus entering other 
tissues.3  
Although malignant melanoma is considered a 
multifactorial disease, the major factor contributing 
to its development is excessive ultraviolet (UV) light 
exposure. 3 Sun exposure may induce DNA damage, 
gene mutation and inflammatory responses, all 
together contributing to the increased risk of skin 
cancer. When skin is exposed to UV radiation, 
cyclooxygenase-2 (COX-2), an inducible enzyme 
generating prostaglandins (PGs) is activated. PGE2 
binds to its G-protein-coupled receptors, EP1, EP2, 
EP3 and EP4, resulting in angiogenesis, decreased 
host immunity, enhanced cancer invasion and 
metastasis.4 
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In this review, we first present the reader with a succinct 
overview of the most important biomolecular pathways in 
tumour metastasis, followed by a detailed discussion of the 
activities of more than 30 natural products upon these targets. 
Other natural products acting through unknown mechanisms of 
action are briefly discussed together at the end of each section.  
2 Tumour metastasis 
Tumour cells have to undergo a remarkable cascade of events 
in order to progress from a benign melanocyte hyperplasia into 
a metastatic melanoma. First, a series of changes in cell motility 
genes will allow the melanoma cell to coordinate the extension, 
adhesion, contraction and detachment necessary to move and 
leave its primary site (Fig. 1). 5 Once this is achieved, the 
invasion of surrounding tissues needs a further series of genetic 
events in order to detach from the primary tumour 
(dissociation), gain access to the lymphatic vessels 
(intravasation) and then enter the target organs (extravasation). 
6, 7 All this sequence of events is also orchestrated by external 
factors, including chemokines, proteases, extracellular matrix 
proteins and growth factors/receptors, integrins, matrix-
degrading enzymes, cell-cell adhesion molecules and cell-cell 
communication proteins. 5, 6, 7, 8 
FIGURE 1 MAY GO HERE (SEE AT THE END OF THE 
DOCUMENT) 
2.1 Cell extension 
The migration process starts with the extension of a 
lamellipodium, a protrusion at the leading edge of the cell (Fig. 
1a). 5 This is underpinned by actin polymerization that provides 
the traction force pushing the membrane forward in the 
direction of the movement. This is stimulated and regulated by 
the Rac protein, which belongs to Rho GTPase family. In 
metastatic tumour cells, this signalling pathway is overactive. 9  
2.2 Adhesion 
Now the extended lamellipodium needs to anchor to the 
extracellular matrix (ECM) via adhesion molecules such as 
integrins, a family of glycoproteins (Fig. 1b). 9 Integrins are 
composed of α and β subunits; the αvβ5 integrin has a central 
role in cellular migration. This can bind to several ECM 
proteins such as fibronectin, laminins and collagen, thereby 
promoting cell attachment and spreading. Various signalling 
pathways, such as active PI3K and protein kinase C, induce the 
assembly of the focal complex in melanoma cells. 6, 12, 13 All 
stages of melanoma are accompanied by the expression of αv, 
while β5 is associated with the vertical growth phase and poor 
prognosis. 7  
Also, there are other adhesion molecules that have the ability to 
mediate adhesion between two similar cells (homotypic 
adhesion) or two different ones (heterotypic interaction), and 
are essential for tumour cell intravasation and extravasation 
such as cadherins. 7, 10 Epithelial (E) and Neural (N) cadherins 
are the major subtypes of cadherin that are involved in 
keratinocyte-melanocyte adhesion. In healthy human skin, E-
cadherin is expressed in melanocytes to ensure their attachment 
to keratinocytes. The intracellular domain of E-cadherin is 
fastened to the actin filaments at the cell edge via catenin, in 
order to resist any mechanical force that may detach a single 
cell from a tissue cell sheet. In malignant melanoma cells, there 
is a lack of expression of the E-cadherin and an overexpression 
of the N-cadherin. The former causing the melanocytes to 
escape the regulatory mechanism of keratinocytes and the latter 
facilitating melanoma cell interactions with fibroblast and 
endothelial cells during invasion into distant tumour sites. 5, 11  
2.3 Secretion of surface protease and contraction 
For the cell to make its way through the three-dimensional 
matrix, surface proteases such as matrix metalloproteinases 
(MMPs) are recruited towards the attachment sites, hydrolysing 
nearby ECM substrates (Fig. 1c). 6 Among 25 members of the 
MMP family, MMP-2, MMP-9 and MT1-MMP are upregulated 
in invasive melanoma cases. 14 MMPs regulation depends on 
many nuclear transcription factors including activating protein-
1 (AP-1), nuclear factor-kappaB (NF-κB), activating 
transcription factor-2 (ATF-2), cAMP response element-
binding (CREB), hypoxia-inducible factor (HIF), as well as a 
number of cell signaling proteins such as tumour necrosis 
factor-α (TNF-α), IL-6, IL-1β, and granulocyte macrophage 
colony-stimulating factor (GM-CSF). 15, 16 In addition, the 
Ras/PI3K/Akt signal pathway regulates cell metastasis through 
the activation of Akt, which eventually controls the expression
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of MMPs and governs many cellular processes implicated in 
tumorigenesis.17  
MMPs are naturally found in a complex with their natural 
inhibitors, known as tissue inhibitors of metalloproteinases 
(TIMPs), but those are reduced in metastatic melanoma cell 
lines.18 Furthermore, MMPs are also involved in the 
vasculogenesis process by enhancing the angiogenic effects of 
pro-inflammatory cytokines e.g. interleukin-2 (IL-2); nitric 
oxide (NO) and vascular endothelial growth factor (VEGF).19  
Once the cell is detached from the ECM substrate, apart from 
the focal points at either edge, contractile force is required to 
allow the bulk of the cell body to move forward, which depends 
on actomyosin contractility (Fig. 1c). Fibre assembly and 
contraction is promoted by RhoC through its binding to the 
downstream effector, the Rho-associated serine/threonine 
kinase (ROCK), controlling the actin dynamics in malignant 
melanoma cells. 5, 9 
2.4 Detachment  
Finally, the trailing edge of the cell detaches from the ECM by 
the concerted action of a number of proteins. Importantly, some 
dedicated kinases such as focal adhesion kinase (FAK) and 
extracellular signal-regulated kinase (ERK) are overexpressed 
in melanoma thus destabilizing focal complexes and facilitating 
cell migration (Fig. 1d). 5, 9 The cell is now free to repeat the 
cycle and keep moving forward eventually leaving the tumour 
primary site. 
3 Melanoma and anti-migratory natural products  
A number of plant derived natural products have been 
described as potential alternative therapies for metastatic 
cancers. 20 The metastatic properties of melanoma cells are a 
major challenge to therapy. Therefore blocking the migratory 
and invasive capacity of malignant cells with phytochemicals 
may open the door to an effective strategy for melanoma 
treatment and/or prevention. 21 We here review those natural 
single chemical entities and herbal extracts which have been 
specifically investigated for their direct in vivo and in vitro 
effects on melanoma migration. For those with identified 
intracellular mechanisms of action we provide their chemical 
structures and map their molecular activities (Fig. 2). 
3.1 Alkaloids 
3.1.1 Berberine 
Berberine 1, an isoquinoline alkaloid, is extracted from the 
rhizome, roots and stem bark of a number of medicinal plants, 
mainly of the Berberis genus such as Berberis aquifolium 
Pursh. It is widely used in traditional medical systems such as 
the Ayurvedic and the Chinese systems. It possesses various 
pharmacological properties such as anti-diabetic and anti-
carcinogenic activity against various tumour cells, with 
insignificant cytotoxicity to normal cells. As tumour 
progression is associated with the overexpression of COX-2 
and PGE2, the effect of berberine on both has been investigated. 
Singh et al. found that treatment of melanoma cells with 
berberine suppressed the invasion of the cells in a dose and 
time-dependent fashion and that this activity was correlated 
with the inhibition of COX-2, the expression of prostaglandin 
receptors EP2 and EP4, and the reduction in the level of PGE 2. 
Moreover, similar effects were detected in transfected cells 
with COX-2 small interfering RNA, confirming that COX-2 is 
a therapeutic target for berberine. In addition, this alkaloid was 
able to inhibit TPA- and PGE2-promoted cell migration in 
melanoma cells with reduced levels of NF-κB, The anti-
migratory effect of berberine was not due to inhibition of cell 
viability or induction of cell apoptosis. 22 Interestingly, 
berberine is a generator of reactive oxygen species, and this 
leads to a reduction of the activity of ERK-1/2, ATF-2 and 
CREB. Moreover, berberine was able to inhibit lung metastasis 
in melanoma-bearing C57BL/6 mice models, demonstrating its 
anti-metastatic potential in melanoma cells. 23, 24  
Berberine further suppresses the tumourgenicity of melanoma 
cells via its anti-angiogenic action in vitro and in vivo. It 
inhibited several pro-angiogenic factors, such as VEGF, 
inducible nitric oxide synthase (iNOS), and HIF, as well as pro-
inflammatory mediators such as IL-1β, IL-6, TNF-α, and GM-
CSF. It also elevated anti-angiogenic factors like IL-2 and 
TIMP, leading to the suppression of tumour-directed capillary 
formation.19 
3.1.2 Harmine 
Harmine 2, is a naturally occurring beta-carboline alkaloid 
present in a number of medicinal plants such as Peganum 
harmala L. It is frequently used in folk medicine for the 
treatment of various diseases, as it is known for its 
neuropharmacological, anti-bacterial, anti-plasmodial and anti-
tumour effects. In vitro and in vivo experiments conducted by 
Hamsa and Kuttan have shown the potential anti-migrative 
properties of harmine; it has inhibited tumour nodule formation 
in the lungs of melanoma-bearing C57BL/6 mice and reduced 
various biochemical parameters associated with lung 
metastasis. The reported activity was associated with the down-
regulation of the expression of pro-metastatic genes, such as 
MMP-9, ERK, and VEGFs, which play a major role in 
melanoma cell invasion. 15 Another study reported that harmine 
displayed an anti-angiogenic effect, which was linked to the 
inhibition of tumour-directed capillary formation in vivo. A 
significant reduction of the level of serum pro-angiogenic 
factors such as VEGF and NO was detected in harmine-treated 
animals. Moreover, harmine deactivated NF-κB –as well as 
other transcription factors like CREB and ATF-2- resulting in 
the inhibition of COX-2, iNOS and MMPs expression, all of 
which are involved in cancer progression. 25 
 
O
O
N
+
O
O
N
H
NO
N
H
NH
O
OH
OH
3
1 2
 
HIGHLIGHT Natural Product Reports 
4  |  J. Name. , 2012, 00,  1-3  This journal is © The Royal Society of Chemistry 2012 
3.1.3 Ipobscurine 
Ipobscurine 3 is an indole alkaloid extracted from Ipomoea 
obscura (L.) Ker Gawl., which exhibits anti-inflammatory and 
immunomodulatory activity. The migratory capacity of 
melanoma cells was reduced by ipobscurine treatment which 
was associated with a significant decrease in the production of 
MMPs and the expressions of VEGF, COX-2, and NO 
synthase. In addition, ipobscurine elevated TIMP-1 and IL-2, 
whereas the high levels of pro-inflammatory factors such as IL-
1β, IL-6, TNF-α, and GM-CSF were reduced in ipobscurine-
treated animals. 26 
3.1.4 α-Solanine 
α-Solanine 4 is a glycoalkaloid that accumulates under certain 
conditions in sprouts and tubers of the Solanaceae species such 
as Solanum nigrum L. The results of in vitro studies 
demonstrated that non-toxic doses of α-solanine suppressed the 
phosphorylation of PI3K and Akt without effecting the 
phosphorylation of ERK. The activity of MMP-2/9 and its 
regulator, NF-κB, were inhibited when melanoma cells were 
exposed to this phytochemical. Taken together, the data 
revealed α-solanine to be a new anti-metastatic agent. 27 
3.1.5 10-Methoxy-9-nitrocamptothecin (MONCPT) 
MONCPT 5 is a semisynthetic derivative of camptothecin, an 
anticancer alkaloid isolated from Camptotheca acuminate 
Decne., which acts as a topoisomerase I inhibitor. These in vivo 
and in vitro results indicate that MONCPT decreased B16F10 
pulmonary metastasis in tumour-bearing C57BL/6 mice and 
suppressed the cell invasion and migration without any 
cytotoxic effects. This was associated with a reduction in the 
secretion of MMP-9 and VEGF, and expression of HIF-1α. 
Moreover, it suppressed the phosphorylation level of ERK in 
B16F10 cells. 28 
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3.1.6 Punarnavine 
Punarnavine 6, is a quinolizidine alkaloid of unknown structure 
isolated from Boerhaavia diffusa L. It exhibits analgesic, anti-
inflammatory, hepato-protective, immunomodulatory and anti-
proliferative properties. Its anti-metastatic properties were 
investigated using B16F-10 melanoma cells in C57BL/6 mice, 
and the administration of punarnavine significantly improved 
the survival rate of the metastatic tumour-bearing animals. This 
improvement was associated with the reduction in MMP-2, 
MMP-9 ERK-1/2 and VEGF in the lung tissue of metastasis-
induced animals. 29 
3.1.7 Other alkaloids 
The anti-migratory properties of other seven alkaloids have 
been reported in experimental melanoma models without full 
elucidation of their mode of action. Evodiamine is one of the 
main constituents of Evodia rutaecarpa (A. Juss.) Hook.f. & 
Thomson and has been shown to inhibit melanoma cell 
invasion in vitro in a concentration manner. 30 In addition, 
several anti-cancer agents were investigated for their effects on 
the migration process, including taxol (from Taxus brevifolia 
Nutt.), harringtonine and homoharringtonine (from 
Cephalotaxus hainanensis H.L.Li). These agents were found to 
be effective for the inhibition of cell invasion and migration of 
B16-BL6 cells. 31 As taxol stabilizes microtubules, it causes 
cytoskeletal changes leading to a reduction in the metastatic 
properties of bladder cancer cells; 32 however the impact of 
taxol on the cytoskeleton and metastatic properties of 
melanoma cells remains to be investigated. Moreover, 
sanguinarine, extracted from Sanguinaria canadensis L., 
reduced the tumour burden in melanoma-bearing C57BL/6 
mice and in a human tumour xenograft grown in 
immunodeficient mice. 21 Two other alkaloids, colchicine (from 
Colchicum autumnale L.) and cytochalasin B (from Curvularia 
lunata (Wakker) Boedijn.), were able to suppress tumour 
metastasis in C57/BL6 mice given IV injections of B16-F10 
cells as well as to reduce the rate of migration from agarose 
droplets and the formation of homotypic aggregates.33 
3.2 Polyphenols 
3.2.1 Genistein  
Genistein 7 is a constituent of Genista tinctoria L. which is 
endowed with several pharmacological properties such as anti-
neoplastic and estrogenic activities. A recent report has 
indicated that genistein blocks the migration of melanoma cells 
without showing obvious cellular cytotoxicity at low doses. It 
seems to suppress early adhesion-induced protein tyrosine 
phosphorylation of focal complex proteins that results in an 
impairment of cell–ECM interaction. The result is a decreased 
invasive potential of B16-BL6 cells through the basement 
membrane. 34 Moreover, it significantly reduced cell motility 
and experimental pulmonary metastatic foci in C57BL/6 mice, 
as well as tumour-induced angiogenesis. 35, 36 
3.2.2 Proanthocyanidins  
Proanthocyanidin 8 gives name to a large class of polyphenols. 
It have been reported to exhibit anti-carcinogenic effects in 
some tumour models. They exist in a variety of plant species 
such as Theobroma cacao L. They are usually present in 
complex mixtures made up of dimmers, trimers, tetramers, and 
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oligomers of monomeric catechins and/or (-)-epicatechins. Due 
to this complexity, it is believed that their melanoma 
preventative effects is linked to the synergistic effects of some 
of these constituents, which in addition to being cytotoxic or 
antimigratory are able to act as sun blockers, thus preventing 
UV radiation-induced skin cancer in vivo. Vaid et al. have 
reported that treating melanoma cells with proanthocyanidins 
resulted in the concentration-dependent inhibition of cell 
migration, which was associated with the reduction in PGE2 
production and down-regulation of the expression of COX-2. 
Proanthocyanidins significantly blocked the phosphorylation of 
ERK-1/2 and the promoted cell migration induced by TPA as 
the tumour promoter mediating CO-2 expression. In addition, 
proanthocyanidins were able to suppress NF-κB activity linked 
with COX-2 regulation. Moreover, adhesion molecules 
involved in the process of epithelial transition in melanoma 
cells were upregulated, such as E-cadherin, and mesenchymal 
molecules (fibronectin and N-cadherin) were decreased due to 
proanthocyanidin treatment. 37  
3.2.3 Anthocyanins  
The anthocyanins are present in the leaves, fruits and flowers of 
many highly pigmented plants and are reputed to possess 
antibacterial, antibiotic, anti-inﬂammatory, anti-oxidative, and 
immune-modulatory properties in folk medicine. Non-cytotoxic 
concentrations of a total extract of anthocyanins from Morus 
alba L. have been shown to inhibit the in vitro migratory 
capacity of melanoma cell in a Boyden chamber assay. Also, 
the expression of MMP-2/9, Ras, PI3K, Akt, and NF-κB in 
C57BL/6 mice induced with B16-F1 cells were reduced, and 
this was accompanied by a reduction of pulmonary colonies in 
mice. Cyanidin-3-O-β-glycosides 9 are some of the most 
abundant anthocyanins in mulberries. 17  
 
3.2.4 Silymarin 
Silymarin 10 is a flavonoid complex isolated from milk thistle 
(Silybum marianum Gaertn.) and is composed up to 90% of 
silibinin 10a plus other isomers such as isosilybin 10b, 
silychristin 10c and silydianin 10d. There have been several 
reports that silymarin possesses anti-inflammatory, anti-
oxidative and chemopreventative, and anti-carcinogenic 
properties. The topical application of silymarin has been shown 
to inhibit ultraviolet radiation-induced skin carcinogenesis in 
SKH-1 hairless mice and to reduce skin tumourgenesis, in a 
study showing that tumour incidence, tumour multiplicity and 
tumour growth were decreased. Vaid et al. studied the anti-
metastatic effects of silymarin in two special melanoma cell 
lines possessing constitutively active or inactive Wnt/β-catenin 
signalling capabilities, respectively. As a result, they 
demonstrated that this flavonoid inhibits β-catenin translocation 
with subsequent down-regulation of MMPs expression. These 
observations confirm that β-catenin is the molecular target of 
silymarin. 38  
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3.2.5 Oroxylin A 
Oroxylin A 11, a flavonoid extracted from Scutellaria 
baicalensis Georgi, was able to suppress the expression and the 
activity of MMP-2/9, as detected by gelatin zymography, real-
time PCR and western blotting analysis. The level of TIMP-2 
was elevated and phosphorylation of ERK-1/2 and AP-1 was 
suppressed, which was associated with the inhibition of lung 
metastasis of B16-F10 cells in vivo. 39  
3.2.6 Quercetin and apigenin 
Quercetin 12 and apigenin 13 have been very much researched 
for their anti-oxidant, anti-inflammatory and anti-cancer 
properties. They are found together in commonly used fruits 
and vegetables such as parsley (Petroselinum crispum (Mill.) 
Fuss). They signiﬁcantly decreased lung colonization by B16-
BL6 in treated syngeneic C57BL/6N mice in a dose-dependent 
manner. 40  Quercetin had anti-migratory effects against 
melanoma both alone and in combination with sulforaphane. 
The inhibitory effect of quercetin was due to a reduction of 
MMP-9 expression in the mouse tumours. 41 
3.2.7 Catechins 
Catechins 14 are a class of flavonoids best known for their 
prominence in tea leaves (Camellia sinensis (L.) Kuntze). They 
exhibit a number of physiological effects and health benefits, 
including antioxidant, anti-microbial and anti-carcinogenic 
activity against various cancer cells. Several catechins have 
been evaluated for their anti-migratory properties against 
melanoma cells, and the strength of their inhibitory effect is as 
follows: (−)-epigallocatechin-3-gallate (EGCG) 14a > (−)-
epigallocatechin 14b > (−)-epicatechin-3-gallate 14c > (−)-
gallocatechin 14d > (−)-epicatechin 14e. 42 
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EGCG -the most effective catechin- has been shown to inhibit 
melanoma cell migration in vitro and in vivo through multiple 
mechanisms and different molecular targets. The expression of 
COX-2 was diminished in melanoma cells after exposure to 
EGCG, resulting in the reduction of the levels of both PGE2 and 
its receptors, EP2 and EP4. This was associated with the 
inhibition of NF-κB, the upstream regulator of COX-2 
expression that is implicated in the development of 
inflammation-induced cancer. 42 In addition, EGCG was able to 
restore the level of epithelial adhesion molecules such as 
cadherin-E and to suppress the level of mesenchymal 
biomarkers such as fibronectin and N-cadherin in melanoma 
cells. Wu and colleagues demonstrated the up-regulation of the 
expression of E-cadherin in a time and concentration manner.43 
Interestingly, EGCG inhibits melanoma cellular migration 
without affecting cell viability or inducing cellular death, and 
no anti-migratory effect was observed in normal human 
epidermal melanocytes. These observations suggest that EGCG 
suppresses melanoma invasion via the reduction of the 
expression of COX-2 and PGE2 receptors and targeting of the 
melanoma cell interactions with the surrounded epithelial and 
mesenchymal cells.42 Liu and colleagues reported that, EGCG 
inhibited the activity of MMP-9, tyrosine phosphorylation of 
FAK and cell spreading on fibronectin, collagen, and matrigel. 
A significant reduction in the number of pulmonary metastases 
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in Male Balb/c mice bearing B16-F3m melanoma was observed 
after EGCG treatment. Importantly, they reported on the 
synergistic effect of the combination of EGCG and dacarbazine 
in reducing lung metastasis in these mice, thereby increasing 
their survival rate, suggesting the clinical potential of EGCG in 
melanoma. 44 
Furthermore, the potential of EGCG in angiogenesis has been 
also investigated. It was found to suppress the phosphorylation 
of Akt in tumour-associated endothelial cells and VEGF. 45 
This was accompanied by the regulation of pro-inflammatory 
cytokines such as IL-1β, IL-6, TNF-α, and GM-CSF. 
Furthermore, EGCG elevated the level of anti-tumour factors 
(IL-2 and TIMP-1) and decreased the level of angiogenesis 
promoters (NO and VEGF) as well as mRNA levels of VEGF 
in B16F-10 melanoma cells. 46 
3.2.8 Curcumin 
Curcumin 15, is a pigmented product obtained from the 
rhizome of Curcuma longa L., which is traditionally used to 
treat inflammatory diseases. Some authors have demonstrated 
its inflammatory, anti-viral and anti-tumour properties. 
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Its anti-invasive properties have been investigated with regard 
to melanoma cells by Menon et al. They found that curcumin 
downregulated the expression of MMPs and NF-κB-mediated 
MMP-2 activation, and also inhibited the expression of MMPs 
in osteopontin-induced cells migration. 47 The in vivo inhibitory 
effect of curcumin was demonstrated through the suppression 
of lung metastasis induced by B16-F10 melanoma cells in 
C57BL/6 mice. 48 Also, curcumin has been shown to inhibit the 
phosphorylation of Src kinase and STAT3 pathway through the 
down-regulation of phosphatase of regenerating liver-3 (PRL-
3), which plays a role in cancer metastasis. 49 
3.2.9 Amentoflavone 
Amentoflavone 16 is a bioflavonoid found in various plants 
including Ginkgo biloba L. and Hypericum perforatum L. 
Several in vitro properties of amentoflavone have been 
reported, such as anti-malarial and anti-cancer activities. A 
study by Tarallo et al. showed that amentoflavone blocked the 
interaction and phosphorylation of VEGF with its receptors, 
VEGF receptors 1 and 2 (VEGFR-1/-2). Moreover, it inhibited 
endothelial cell migration and capillary-like tube formation. 50 
In vivo experiments revealed that it decreased the level of 
various endogenous factors such as IL-1β, IL-6 and GM-CSF 
and it elevated the level of IL-2 and TIMP-1, confirming that 
amentoflavone acts as an antiangiogenic molecule. In addition, 
it reduced experimental tumour metastasis in syngeneic 
C57BL/6 mice implanted with B16 cells. Guruvayoorappan and 
Kuttan demonstrated that amentoflavone was able to reduce the 
mRNA expression of MMP-2/9, ERK-1/2 and TNF-α in lung 
tissues while the expression of STAT-1 and nm23, which play a 
key role in the acquisition of melanoma metastatic ability, was 
increased. 51, 52 
3.2.10 Capsaicin 
Capsaicin 17 is the main active compound in the chili pepper 
(Capsicum frutescens L.), one of the most commonly used 
spices in the world, and other plants of the Capsicum genus. 
Analgesic, anti-inflammatory and anti-cancer activities of 
capsaicin through the induction of apoptosis have been 
reported. The anti-migratory activity of capsaicin on melanoma 
cells was correlated with inhibition of the PI3K/Akt/Rac1 
signal pathway. The observed activity was associated with the 
down-regulation of PI3K and its downstream target, Akt, as 
well as the inhibition of Rac1 activity. 53 The potential of 
capsaicin to inhibit melanoma invasion has been investigated 
by Min et al. and it has been related to the inhibition of VEGF 
activity and capillary-like tube formation of primary cultured 
human endothelial cells. 43 
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3.2.11 Resveratrol and pterostilbene 
Resveratrol 18a is a natural phenol which possesses antioxidant 
and inflammatory properties, found in Polygonum cuspidatum 
Willd. ex Spreng and red wine. Its anti-migratory properties 
against melanoma cells have been shown in vitro and in vivo. 
These effects seem to be related to the deactivation of Akt, as 
determined by a combination of real-time PCR and western blot 
analysis. 54 However, the activity of resveratrol is limited by its 
low bioavailability. Pterostilbene 19, which is a related natural 
polyphenol existing in a high concentration in berries and 
grapes such as Vitis vinifera L., shows similar activity to 
resveratrol but with the advantage of a longer half-life in vivo. 
In fact, half-life of pterostilbene after I.V. administration to 
mice was five fold longer (t1/2= 77.9 min) than this of 
resveratrol (t1/2= 14.4 min). 
55 Furthermore, the I.V. 
administration of pterostilbene in C57BL/6J mice inhibits the 
metastatic growth of melanoma cells to the liver. The anti-
metastatic mechanism involves the inhibition of the expression 
of vascular adhesion molecule 1, which plays a central role in 
the migration process, leading to a reduction in the rate of 
adhesion between melanoma cells and the vascular 
endothelium. 56 
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The enormous potential of resveratrol led to the synthesis of 
derivatives to enhance its pharmacological activities; one of 
these is the stilbene 3,3',4,4',5,5'-hexahydroxy derivative 18b . 
It has been shown to decrease the migratory properties of 
melanoma cells in vitro through interference with integrin-
linked protein kinase and ROCK-1, indicating its role in the 
inhibition of mesenchymal and amoeboid cell migration. 57 
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18a R1,R2,R3,R5=H       R4,R6=OH
18b R1,R2,R3,R4,R5,R6=OH
19 R1,R3,R5=H   R2 = OH    R4,6=OCH3  
 
3.2.12 Gallic acid 
Gallic acid 20 is a common plant metabolite known to possess 
antibacterial, antifungal, antimalarial, antioxidant and antiviral 
action. The inhibitory potential of this simple phenol against the 
invasion of melanoma cells is mediated, at least in part, through 
the Ras/ERK signalling pathways leading to the reduction of 
MMP-2/9 gene expression and protein levels. 58 
3.2.13 Gambogic acid 
Gambogic acid 21 is a haemostatic and an antiseptic 
xanthonoid isolated from the resin of Garcinia hanburyi 
Hook.f. It has been reported to inhibit the metastatic potential 
of the B16-F10 melanoma cell line in vitro and in vivo. The 
down-regulation of α4 integrin expression in association with 
negligible effects on the expression of α5 and β1 integrin was 
involved in this anti-metastatic action, as detected by 
flowcytometry and western blot analyses. 59 
3.2.14 Other flavonoids 
The effects of two other flavonoids on the invasion and 
metastasis of B16 cells have been reported without description 
of the mechanisms of action. Ampelopsin, derived from Cedrus 
deodara (Roxb. ex D.Don) G.Don, reduced the in vitro ability 
of these melanoma cells to migrate and this observation 
correlated with a reduction in the number of metastases in 
treated C57BL/6 mice.60 In addition, a quercetin derivative 
extracted from Cladocolea micrantha (Eichler) Kuijt, bearing 
an O-arabinofuranosyl-(13)-rhamnoside moiety, promoted a 
twofold inhibition of melanoma cell migration in vitro. 61  
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3.3 Vitamin-related compounds  
3.3.1 Retinoic acid 
Retinoic acid 22 is an all-trans metabolite of vitamin A that 
mediates gene transcription and regulates a wide variety of 
normal cellular processes such as cell proliferation and 
differentiation. Retinoic acid exhibits a pronounced anti-
invasive effect and appears to inhibit the adhesion of melanoma 
cells to the extracellular matrix components type I collagen and 
laminin. Using fluorescence microscopy, Helige et al. have 
demonstrated that it can modulate the organization of the actin 
cytoskeleton. 62 Also, retinoic acid reduced the level of 
collagenolytic enzymes and type IV collagenase messenger 
RNA and decreased the activity of tissue plasminogen 
activator. Moreover, retinoic acid treatment was associated with 
a reduction in the expression of cell-surface receptors for 
motility factors. 63 In addition, retinoic acid was able to block 
the neovascularization process by elevating the production of 
IL-2 and TIMP-1 in treated animals and blocking the activation 
of NF-κB subunits, p65, p50, c-Rel, and other transcription 
factors such as c-fos, ATF-2 and CREB protein in melanoma 
cells. 64  
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3.3.2 Riboflavin photoproducts 
Irradiation of Vitamin B2 with UV light leads to the formation 
of a complex mixture of photolytic products (iRFs) endowed 
with interesting biological activities. Among those, they disrupt 
melanoma cell migration, increase TIMP expression and 
suppress the activity and expression of MMP in treated cells. 
This is due , at least in part, by targeting the hedgehog pathway, 
which regulates the metastasis of melanoma. iRFs upregulate 
SUFU, an inhibitor of this pathway, and downregulate GLI1 
and PTCH. In addition, they reduce the incidence of pulmonary 
metastases in treated C57Bl/6 mice. 65 
3.4 Terpenoids 
3.4.1 Artemisinin 
Artemisinin 23 is a known anti-malarial agent; it is a 
sesquiterpene derived from Artemisia annua L., which is used 
in traditional Chinese medicine as an antipyretic. It has been 
shown to target the adhesion capacity of melanoma cells via the 
down-regulation of α5β3 integrin expression, as well as 
reducing MMP-2 production, revealing the potential 
chemotherapeutic effect of artemisinin in melanoma treatment. 
66  
3.4.2 Carnosol, Atractylenolides I and II 
Carnosol 24, a component of Rosmarinus officinalis L., as well 
as atractylenolides I 25 and II 26, from Atractylodes 
macrocephala Koidz, have shown potent in vitro activity 
against melanoma migration. All of the compounds inactivated 
ERK phosphorylation and inhibited Akt, suggesting that the 
PI3K/Akt signalling pathway is involved in their action. 67, 68 
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Carnosol inhibited MMP activity as well as NF-κB and AP-1 
binding activity, thereby restricting the invasive ability of 
melanoma cells. 68  
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3.4.3 Thujone and Vernolide-A 
Thujone 27 is a monoterpene found in a number of plants, e.g. 
Thuja standishii Gordon, and vernolide-A 28 is a sesquiterpene 
lactone present in Vernonia cinerea L. Their anti-metastasis 
properties have been reported, where the administration of both 
compounds significantly suppressed tumour nodule formation 
in the lungs of C57BL/6 mice transplanted with B16 melanoma 
cells. These effects were accompanied by the down-regulation 
of the expression of MMP-2/9, ERK-1/2, and VEGF in the lung 
tissue of treated animals. 69, 70 In addition, thujone treatment 
reduced the production of pro-inflammatory factors such as 
TNF-α, IL-1β, IL-6, and GM-CSF, whereas the expression of 
TIMP-1/2 was elevated. 69 
3.4.4 Parthenolide 
The sesquiterpene lactone parthenolide 29 is the putatitve active 
principle of Tanacetum parthenium (L.) Sch.Bip. (Feverfew), a 
herbal medicine used to treat several conditions, including 
inflammation, migraine, menstrual irregularities, fever and 
rheumatoid arthritis. Parthenolide has been found to be a 
potential agent against melanoma migration through its 
inhibitory effect on the constitutive and induced NF-κB 
pathway. It also suppressed IL-8 and MMP-9 expression, which 
are involved in melanoma migration and invasiveness. 71  
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3.4.5 β-Carotene 
Carotenoids are tetraterpenes with multiple biological and 
pharmacological activities; β-carotene 30 is a carotenoid with 
photosynthetic and vitamin A activity present in many edible 
fruits and vegetables such as Daucus carota L. The inhibitory 
effect of β-carotene on melanoma metastasis was associated 
with the prevention of the activation of several subunits of NF-
κB; p65, p50, and c-Rel. It alos elevated the expression level of 
TIMP-1/2 and down-regulated the expression of MMP-2/9, 
prolyl hydroxylase, as well as the lysyl oxidase gene involved 
in the metastasis process. 72  
 
30
 
3.4.6 Other terpenoids 
Oridonin, a diterpenoid isolated from Rabdosia rubescens 
(Hemsl.) H.Hara, has been shown to inhibit the motility of 
melanoma cells in a concentration manner. 73  The treatment of 
C57BL/6 mice induced with metastatic B16F-10 melanoma 
cells with hypoestoxide (from Hypoestes rosea Decne.) and 
ursolic acid (from Ocimum sanctum L.) resulted in a marked 
reduction of lung metastatic colonies. The levels of serum 
VEGF and NO were decreased in ursolic acid-treated animals. 
73, 74, 75  
3.5 Peptides 
3.5.1 Actibind 
Actibind is a T2 RNase extracted and purified from the fungus 
Aspergillus niger van Tieghem. As such, it degrades RNA 
thereby inhibiting protein synthesis and subsequent cell death. 
Actibind is effective as an anti-metastatic agent since it 
inhibited human melanoma cell invasion in vivo and in vitro by 
suppressing the activity of MMP-2 in a dose-dependent manner 
as well as inhibiting pro-MMP-2 collagenase activity in 
melanoma cells. 76 
3.5.2 Glycoproteins  
Gintonin, a novel glycolipoprotein from Panax ginseng 
C.A.Mey., suppressed pulmonary metastasis induced by 
tailvein inoculations of melanoma cells in C57BL/6 mice. Its 
effect in cell migration contrats with minimal inhibition of 
tumour growth and is mediated by its antagonism to 
lysophosphatidic acid receptors. 77 The related iminosugars 
were also able to inhibit pulmonary metastasis of the melanoma 
cells in treated mice, e.g. gem-diamine 1-N-iminosugars related 
to D-glucuronic acid and L-iduronic acid, nojirimycin and D-
glucaro-d-lactam.78 
Peptides from animal origin have been also investigated. 
Hirudin from leeches (Hirudo medicinalis L.) alone or in 
combination with liposomal vinblastine has exhibited a potent 
effect against tumour growth and metastasis of melanoma in 
vivo as well as melanoma adhesion in vitro. 79 The Mohave 
rattlesnake (Crotalus scutulatus Kennicott) venom yields R-
Mojastin 1 that suppressed SK-MEL-28 cell adhesion to 
fibronectin. Furthermore, it inhibited lung tumour colonization 
of melanoma cells in BALB/c mice.80 
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3.6 Herbal extracts 
3.6.1 Prunella vulgaris 
The in vitro and in vivo effects of an aqueous extract from 
Prunella vulgaris L. (PVAE) have been studied. MMP-9 
expression and its mRNA level were diminished via the 
inhibition of the activity of NF-κB as well as blocking the 
phosphorylation of ERK-1/2. PVAE was able to suppress 
melanoma metastasis in tumour-bearing C57BL/6 mice.81 Its 
chemical composition includes alkaloids, saponins, phenolics 
and tannins. 82 
3.6.2 Piper longum 
The anti-metastatic properties of an ethanolic extract of Piper 
longum L. have been investigated in melanoma-bearing 
C57BL/6 mice. The level of cytokines involved in the 
metastasis process, such as IL-1β, IL-6, VEGF, TNF-α and 
GM-CSF, was decreased. On the other hand, IL-2 and TIMP-1 
levels were elevated, reducing the metastatic capacity of 
melanoma cells.83 The phytochemical analysis reveals that the 
herb contains alkaloids such as piperine, lignans and volatile 
oils. 84 Piperine might contribute to the activity of the extract as 
it is a known anti-cancer lead compound, with inhibitory 
activity in the lung metastasis induced by B16F-10 melanoma 
cells in C57BL/6 mice. 85  
 
FIGURE 2 MAY GO HERE (SEE AT THE END OF THE 
DOCUMENT) 
4 Concluding remarks 
Natural products have emerged as a very promising source of 
anti-migratory agents, some of them being considered as 
potential treatment interventions. This review summarizes the 
experimental evidence of the anti-metastatic activity of natural 
products in melanoma and charts the mechanisms of action 
underlying these interesting properties (Fig. 2). Their most 
important intracellular targets appear to be the downstream 
inactivation of a number of nuclear factors, namely NF-B, 
AP1, ATF-2, CREB, and HIF. These effects are mediated, at 
least in part, by the inhibition of important kinases including 
PI3K, RAS, ERK and FAK. Antagonistic effects upon the 
TNF- and EP2 receptors and the function of adhesion 
molecules -including integrin and N-cadherin- were also 
described for a number of them. A majority of the reviewed 
products seem to be selectively acting upon one of these targets 
only, but remarkably some (berberine, harmine, EGCG and 
retinoic acid) are multitargeting several of these key pathways 
holding promise in future clinical studies. 
These compounds could be clinically used on their own or in 
combination with another natural product or drug. The first 
option is only commercially viable when using patentable 
products. This can be achieved by modifying the original 
natural product such as in the case of colchicine and MONCPT 
28. The second one could make use of the natural product as 
such together with an approved drug, for example EGCG in 
combination with dacarbazine, which resulted in an 
improvement in the survival rate of melanoma-bearing mice. 44 
This also applies to the combination of two natural compounds 
such as in the case of quercetin and sulforaphane. 41 
Interestingly, many of the molecules reviewed here could be 
obtained as by-products of the food industry. In some cases, 
nutritional interventions with standardized extracts enriched in 
the active natural product/s could be devised for 
chemoprevention in healthy individuals or improvement of 
cancer prognosis. In addition, some of the compounds 
discussed here are already used for clinical purposes for other 
indications in the form of derivatives such as artesunate, which 
may accelerate their use for melanoma treatment. In summary, 
we here highlight that many natural-derived agents have 
demonstrated their potential in the treatment/prevention of 
migration and how they could be incorporated into melanoma 
therapy. 
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Figure 1 The migration process in cancer cells. 
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Figure 2. Molecular targets of antimigratory natural products. 
 
